BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324. [PMID: 12818276 DOI: 10.1111/j.1572-0241.2003.07457.x] [Cited by in Crossref: 349] [Cited by in F6Publishing: 290] [Article Influence: 18.4] [Reference Citation Analysis]
Number Citing Articles
1 Henderson C, Davis JC. Drug Insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis. Nat Rev Rheumatol 2006;2:211-8. [DOI: 10.1038/ncprheum0157] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheumatic Disease Clinics of North America 2004;30:237-55. [DOI: 10.1016/j.rdc.2004.02.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
3 Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9. [PMID: 17522249 DOI: 10.1634/theoncologist.12-5-601] [Cited by in Crossref: 288] [Cited by in F6Publishing: 234] [Article Influence: 19.2] [Reference Citation Analysis]
4 Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. Eur J Gastroenterol Hepatol 2018;30:612-20. [PMID: 29384798 DOI: 10.1097/MEG.0000000000001078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clin North Am 2006;35:857-66. [PMID: 17129817 DOI: 10.1016/j.gtc.2006.09.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
6 Adelman M, Lyons AB, Hamzavi IH. Comment on "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa". J Am Acad Dermatol 2021;84:e201-2. [PMID: 33253840 DOI: 10.1016/j.jaad.2020.10.095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 van Gennep S, Sahami S, Buskens CJ, van den Brink GR, Ponsioen CY, D'Hoore A, de Buck van Overstraeten A, van Assche G, Ferrante M, Vermeire S, Bemelman WA, D'Haens GR, Löwenberg M. Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy. Eur J Gastroenterol Hepatol 2017;29:338-44. [PMID: 27902515 DOI: 10.1097/MEG.0000000000000798] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A, Petersson J, Thakkar R. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. Journal of Crohn's and Colitis 2014;8:1407-16. [DOI: 10.1016/j.crohns.2014.04.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
9 Scavone C, Sessa M, Clementi E, Corrao G, Leone R, Mugelli A, Rossi F, Spina E, Capuano A. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. BioDrugs 2018;32:607-17. [PMID: 30341487 DOI: 10.1007/s40259-018-0313-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Richards JC, Tay-kearney M, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005;33:461-8. [DOI: 10.1111/j.1442-9071.2005.01062.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 75] [Article Influence: 5.2] [Reference Citation Analysis]
11 Coyle PK, Foley JF, Fox EJ, Jeffery DR, Munschauer FE, Tornatore C. Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy. Mult Scler 2009;15:26-36. [DOI: 10.1177/1352458509347131] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
12 Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ, Breslow RG, Brockow K, Buchheit KM, Cahill KN, Cernadas J, Chiriac AM, Crestani E, Demoly P, Dewachter P, Dilley M, Farmer JR, Foer D, Fried AJ, Garon SL, Giannetti MP, Hepner DL, Hong DI, Hsu JT, Kothari PH, Kyin T, Lax T, Lee MJ, Lee-Sarwar K, Liu A, Logsdon S, Louisias M, MacGinnitie A, Maciag M, Minnicozzi S, Norton AE, Otani IM, Park M, Patil S, Phillips EJ, Picard M, Platt CD, Rachid R, Rodriguez T, Romano A, Stone CA Jr, Torres MJ, Verdú M, Wang AL, Wickner P, Wolfson AR, Wong JT, Yee C, Zhou J, Castells M. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. J Allergy Clin Immunol Pract 2020;8:S16-S116. [PMID: 33039007 DOI: 10.1016/j.jaip.2020.08.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 24.0] [Reference Citation Analysis]
13 Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CSJ, Perowne R, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease: LENALIDOMIDE IN ACTIVE CROHN’S DISEASE. Alimentary Pharmacology & Therapeutics 2007;26:421-30. [DOI: 10.1111/j.1365-2036.2007.03385.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
14 Su S, Yu K, Woung P, Grattagliano I, Portincasa P. Comment: Esomeprazole-Induced Central Fever with Severe Myalgia. Ann Pharmacother 2005;39:1764-1764. [DOI: 10.1345/aph.1e377a] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Bermejo F, San Román AL, Algaba A, Van Domselaar M, Carneros JA, Rivero M, Piqueras B, Paz Valer M. Eficacia de la premedicación con un esteroide y un antihistamínico en la prevención de reacciones infusionales por infliximab. Gastroenterología y Hepatología 2008;31:629-32. [DOI: 10.1016/s0210-5705(08)75809-6] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
16 Puig L, Sáez E, Lozano M, Bordas X, Carrascosa J, Gallardo F, Luelmo J, Sánchez-regaña M, Alsina M, García-patos V. Reacciones a la infusión de infliximab en pacientes dermatológicos. Actas Dermo-Sifiliográficas 2009;100:103-12. [DOI: 10.1016/s0001-7310(09)70227-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790. [PMID: 16979537 DOI: 10.1016/j.berh.2006.06.002] [Cited by in Crossref: 153] [Cited by in F6Publishing: 132] [Article Influence: 10.2] [Reference Citation Analysis]
18 Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). Journal of the American Academy of Dermatology 2007;56:e55-79. [DOI: 10.1016/j.jaad.2006.07.019] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
19 Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK. Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years. J Rheumatol 2014;41:1409-15. [DOI: 10.3899/jrheum.131231] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
20 Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 2016;25:129-43. [DOI: 10.1517/13543784.2016.1126247] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
21 Weber RW. Adverse reactions to biological modifiers. Curr Opin Allergy Clin Immunol. 2004;4:277-283. [PMID: 15238793 DOI: 10.1097/01.all.0000136757.58818.10] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
22 de Vries HS, van Oijen MG, Driessen RJ, de Jong EM, Creemers MC, Kievit W, de Jong DJ. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011;71:7-19. [PMID: 21143496 DOI: 10.1111/j.1365-2125.2010.03760.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
23 Laharie D, Chanteloup E, Chabrun E, Subtil C, Kowo M, El Hanafi K, DE Lédinghen V. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn’s disease primary responders. Aliment Pharmacol Ther. 2009;29:1240-1248. [PMID: 19416134 DOI: 10.1111/j.1365-2036.2009.03997.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
24 Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 2006;5:9-16. [PMID: 16370952 DOI: 10.1517/14740338.5.1.9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
25 de Vries HS, van Oijen MG, van Hoven-van Loo KE, de Jong DJ. Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions. J Clin Gastroenterol 2009;43:387-8. [PMID: 18987555 DOI: 10.1097/MCG.0b013e318178d938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
26 Ahluwalia JP. Immunotherapy in Inflammatory Bowel Disease. Medical Clinics of North America 2012;96:525-44. [DOI: 10.1016/j.mcna.2012.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
27 Babouri A, Roblin X, Filippi J, Hébuterne X, Bigard M, Peyrin-biroulet L. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study. Journal of Crohn's and Colitis 2014;8:161-5. [DOI: 10.1016/j.crohns.2013.08.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
28 Siddiqui MAA, Scott LJ. Infliximab: A Review of its Use in Crohn???s Disease and Rheumatoid Arthritis. Drugs 2005;65:2179-208. [DOI: 10.2165/00003495-200565150-00014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
29 Tsujimura Y, Obata K, Mukai K, Shindou H, Yoshida M, Nishikado H, Kawano Y, Minegishi Y, Shimizu T, Karasuyama H. Basophils Play a Pivotal Role in Immunoglobulin-G-Mediated but Not Immunoglobulin-E-Mediated Systemic Anaphylaxis. Immunity 2008;28:581-9. [DOI: 10.1016/j.immuni.2008.02.008] [Cited by in Crossref: 270] [Cited by in F6Publishing: 239] [Article Influence: 19.3] [Reference Citation Analysis]
30 Pérez-zafrilla B, Ángel Descalzo M, Carmona L. Adverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic Therapy. Reumatología Clínica (English Edition) 2008;4:90-5. [DOI: 10.1016/s2173-5743(08)70164-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis. Modern Rheumatology 2019;29:324-7. [DOI: 10.1080/14397595.2018.1457490] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Vande Casteele N, Breynaert C, Vermeire S, Rutgeerts PJ, Gils A, Van Assche G. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay. Aliment Pharmacol Ther 2011;34:401-3; author reply 404-5. [PMID: 21726254 DOI: 10.1111/j.1365-2036.2011.04726.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
33 Ma D, Wong W, Aviado J, Rodriguez C, Wu H. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease. Am J Gastroenterol 2019;114:352-4. [PMID: 30333541 DOI: 10.1038/s41395-018-0368-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opinion on Biological Therapy 2012;12:179-92. [DOI: 10.1517/14712598.2012.644271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
35 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Zeng-Wang YM, Cares K, Thomas R, El-Baba M. The Effectiveness of Methylprednisolone as a Premedication Among the Pediatric Population for Preventing Infusion-Related Reactions to Infliximab. Gastroenterol Nurs 2021;44:449-54. [PMID: 34690297 DOI: 10.1097/SGA.0000000000000592] [Reference Citation Analysis]
37 Mourad AA, Boktor MN, Yilmaz-Demirdag Y, Bahna SL. Adverse reactions to infliximab and the outcome of desensitization. Ann Allergy Asthma Immunol 2015;115:143-6. [PMID: 26093777 DOI: 10.1016/j.anai.2015.06.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
38 Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Seminars in Arthritis and Rheumatism 2005;34:819-36. [DOI: 10.1016/j.semarthrit.2004.11.006] [Cited by in Crossref: 140] [Cited by in F6Publishing: 118] [Article Influence: 8.2] [Reference Citation Analysis]
39 Patel SV, Khan DA. Adverse Reactions to Biologic Therapy. Immunology and Allergy Clinics of North America 2017;37:397-412. [DOI: 10.1016/j.iac.2017.01.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
40 Lamireau T, Cézard J, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies J, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J. Efficacy and Tolerance of Infliximab in Children and Adolescents with Crohn’s Disease: . Inflammatory Bowel Diseases 2004;10:745-50. [DOI: 10.1097/00054725-200411000-00008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
41 Iwamoto H, Matsubara T, Nakazato Y, Namba K, Takeda Y. Decreased expression of CD200R3 on mouse basophils as a novel marker for IgG1-mediated anaphylaxis. Immun Inflamm Dis 2015;3:280-8. [PMID: 26417442 DOI: 10.1002/iid3.67] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
42 Solé D, Spindola MAC, Aun MV, Araújo Azi LMT, Bernd LAG, Garcia DB, Capelo AV, Cumino DO, Lacerda AE, Lima LC, Morato EF, Nunes RR, Rubini NPM, da Silva J, Tardelli MA, Watanabe AS, Curi EF, Sano F. [Update on perioperative hypersensitivity reactions: joint document from the Brazilian Society of Anesthesiology (SBA) and Brazilian Association of Allergy and Immunology (ASBAI) - Part II: etiology and diagnosis]. Braz J Anesthesiol 2020;70:642-61. [PMID: 33308829 DOI: 10.1016/j.bjan.2020.08.008] [Reference Citation Analysis]
43 Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2927-36. [PMID: 23867874 DOI: 10.1097/MIB.0b013e31829aad16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
44 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
45 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
46 Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8. [PMID: 19405000 DOI: 10.1002/art.24463] [Cited by in Crossref: 127] [Cited by in F6Publishing: 115] [Article Influence: 9.8] [Reference Citation Analysis]
47 Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007;7:393-403. [PMID: 17873578 DOI: 10.1097/ACI.0b013e3282ef96df] [Cited by in Crossref: 34] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
48 Sehgal VN, Pandhi D, Khurana A. Biologics in dermatology: adverse effects. Int J Dermatol 2015;54:1442-60. [PMID: 26147909 DOI: 10.1111/ijd.12802] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
49 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
50 Montañez MI, Mayorga C, Bogas G, Barrionuevo E, Fernandez-Santamaria R, Martin-Serrano A, Laguna JJ, Torres MJ, Fernandez TD, Doña I. Epidemiology, Mechanisms, and Diagnosis of Drug-Induced Anaphylaxis. Front Immunol 2017;8:614. [PMID: 28611774 DOI: 10.3389/fimmu.2017.00614] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 9.2] [Reference Citation Analysis]
51 Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, De Sarro C, Suraci E, Marasco R, Imeneo M, Russo E, Abenavoli L, De Sarro G, Luzza F. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep 2021;94:289-97. [PMID: 34430850 DOI: 10.15386/mpr-1897] [Reference Citation Analysis]
52 Fréling E, Peyrin-biroulet L, Poreaux C, Morali A, Waton J, Schmutz J, Guéant J, Barbaud A. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. European Journal of Gastroenterology & Hepatology 2015;27:1200-8. [DOI: 10.1097/meg.0000000000000436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.9] [Reference Citation Analysis]
53 Vizcarra C, Belcher D. Management of the Patient Receiving Parenteral Biologic Therapy: . Journal of Infusion Nursing 2006;29:63-71. [DOI: 10.1097/00129804-200603000-00003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
54 Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clin Proc. 2017;92:1088-1103. [PMID: 28601423 DOI: 10.1016/j.mayocp.2017.04.010] [Cited by in Crossref: 111] [Cited by in F6Publishing: 92] [Article Influence: 22.2] [Reference Citation Analysis]
55 Fefferman DS, Farrell RJ. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:497-503. [PMID: 15867590 DOI: 10.1097/01.mib.0000161536.97412.41] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther 2004;6 Suppl 2:S12-8. [PMID: 15228616 DOI: 10.1186/ar995] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
57 Moss IB, Moss MB, Reis DSD, Coelho RM. Reações infusionais imediatas a agentes imunobiológicos endovenosos no tratamento de doenças autoimunes: experiência de 2.126 procedimentos em um centro de infusão não oncológico. Revista Brasileira de Reumatologia 2014;54:102-9. [DOI: 10.1016/j.rbr.2014.03.004] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
58 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
59 Vashisht P, O'dell J. Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences. Expert Opin Biol Ther 2017;17:989-99. [PMID: 28594252 DOI: 10.1080/14712598.2017.1340453] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
60 Sandhu A, Alameel T, Dale CH, Levstik M, Chande N. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther. 2012;36:159-165. [PMID: 22616981 DOI: 10.1111/j.1365-2036.2012.05141.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
61 Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015;8:143-59. [PMID: 25949527 DOI: 10.1177/1756283X15576462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
62 Everds NE, Tarrant JM. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicol Pathol 2013;41:280-302. [PMID: 23471185 DOI: 10.1177/0192623312467400] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
63 Kawaguchi T, Kawazoe Y, Kamoi K, Miyanaga M, Takase H, Sugita S, Mochizuki M. Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75-80. [PMID: 24129677 DOI: 10.1007/s10384-013-0283-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
64 Kelsall J, Rogers P, Galindo G, De Vera MA. Safety of Infliximab Treatment in Patients with Rheumatoid Arthritis in a Real-world Clinical Setting: Description and Evaluation of Infusion Reactions. J Rheumatol 2012;39:1539-45. [DOI: 10.3899/jrheum.110956] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
65 Sanromán Álvarez L, de Castro Parga ML, Hernández Ramírez V, Clofent Vilaplana J, Pineda Mariño JR, Hermo Brión J, Cid Gómez L, Martínez Turnes A, Domínguez Rodriguez F, Estévez Boullosa P, Rodríguez-prada J. Protocolo para la monitorización de la terapia inmunosupresora y biológica en una unidad de atención integral a pacientes con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2012;35:602-7. [DOI: 10.1016/j.gastrohep.2012.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Davis JC, Mease PJ. Insights Into the Pathology and Treatment of Spondyloarthritis: From the Bench to the Clinic. Seminars in Arthritis and Rheumatism 2008;38:83-100. [DOI: 10.1016/j.semarthrit.2007.10.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
67 McConnell J, Parvulescu-Codrea S, Behm B, Hill B, Dunkle E, Finke K, Snyder K, Tuskey A, Cox D, Woodward B. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. World J Gastrointest Pharmacol Ther 2012; 3(5): 74-82 [PMID: 23515325 DOI: 10.4292/wjgpt.v3.i5.74] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
68 Breynaert C, Ferrante M, Fidder H, Van Steen K, Noman M, Ballet V, Vermeire S, Rutgeerts P, Van Assche G. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol. 2011;106:778-785. [PMID: 21407184 DOI: 10.1038/ajg.2011.61] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
69 Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, Ghosh S, Bhala N. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:664-80. [DOI: 10.1111/apt.15097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
70 Choi E, Kim S. Anaphylactic reaction following reversal of nondepolarizing muscle relaxant during general anesthesia: a case report. Int Med Case Rep J 2017;10:271-4. [PMID: 28848366 DOI: 10.2147/IMCRJ.S142597] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
71 Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther. 2012;35:1397-1407. [PMID: 22519466 DOI: 10.1111/j.1365-2036.2012.05100.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
72 Quezada SM, Mclean LP, Cross RK. Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology 2018;12:1183-91. [DOI: 10.1080/17474124.2018.1545574] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
73 Rudwaleit M, Sieper J. Infliximab for the treatment of ankylosing spondylitis. Expert Opin Biol Ther 2005;5:1095-109. [PMID: 16050786 DOI: 10.1517/14712598.5.8.1095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
74 Stuby U, Biesenbach G, Pieringer H. Administration of infliximab in general practitioners’ offices is safe. Clin Rheumatol 2007;26:1863-6. [DOI: 10.1007/s10067-007-0590-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
75 van Schie KA, Kruithof S, Ooijevaar-de Heer P, Derksen NIL, van de Bovenkamp FS, Saris A, Vidarsson G, Bentlage AEH, Jiskoot W, Romeijn S, Koning RI, Bos E, Stork EM, Koeleman CAM, Wuhrer M, Wolbink G, Rispens T. Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies. Ann Rheum Dis 2018;77:1471-9. [DOI: 10.1136/annrheumdis-2018-213299] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
76 Kozma GT, Mészáros T, Weiszhár Z, Schneider T, Rosta A, Urbanics R, Rosivall L, Szebeni J. Variable association of complement activation by rituximab and paclitaxel in cancer patients in vivo and in their screening serum in vitro with clinical manifestations of hypersensitivity: a pilot study. European Journal of Nanomedicine 2015;7. [DOI: 10.1515/ejnm-2015-0026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
77 Miki H, Okamoto A, Ishigaki K, Sasaki O, Sumitomo S, Fujio K, Yamamoto K. Cardiopulmonary Arrest After Severe Anaphylactic Reaction to Second Infusion of Infliximab in a Patient with Ankylosing Spondylitis. J Rheumatol 2011;38:1220-1220. [DOI: 10.3899/jrheum.110076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
78 Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. Journal of Crohn's and Colitis 2012;6:108-11. [DOI: 10.1016/j.crohns.2011.08.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
79 Hirayama F, Yasui K, Matsuyama N, Okamura-shiki I. Possible Utility of the Basophil Activation Test for the Analysis of Mechanisms Involved in Allergic Transfusion Reactions. Transfusion Medicine Reviews 2018;32:43-51. [DOI: 10.1016/j.tmrv.2017.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
80 Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Advanced Drug Delivery Reviews 2006;58:686-706. [DOI: 10.1016/j.addr.2006.03.011] [Cited by in Crossref: 235] [Cited by in F6Publishing: 202] [Article Influence: 14.7] [Reference Citation Analysis]
81 Sugiura F, Kojima T, Oba M, Tsuchiya H, Ishiguro N. Anaphylactic reaction to infliximab in two rheumatoid arthritis patients who had previously received infliximab and resumed. Modern Rheumatology 2014;15:201-3. [DOI: 10.3109/s10165-005-0386-x] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
82 Shin D, Kim Y, Kim YS, Körnicke T, Fuhr R. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects. BioDrugs 2015;29:381-8. [PMID: 26577771 DOI: 10.1007/s40259-015-0150-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
83 He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10(3): 309-318 [PMID: 14760748 DOI: 10.3748/wjg.v10.i3.309] [Cited by in CrossRef: 168] [Cited by in F6Publishing: 161] [Article Influence: 9.3] [Reference Citation Analysis]
84 Li LY, Brimhall AK, Menter A. Systemic therapy for moderate-to-severe psoriasis. Expert Review of Dermatology 2014;1:77-92. [DOI: 10.1586/17469872.1.1.77] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev. 2011;10:563-568. [PMID: 21570495 DOI: 10.1016/j.autrev.2011.04.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
86 Hata T, Kavanaugh A. Rheumatoid arthritis in dermatology. Clin Dermatol 2006;24:430-7. [PMID: 16966022 DOI: 10.1016/j.clindermatol.2006.07.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
87 Jairath V, Mcdonald JW, Feagan BG. Ulcerative Colitis. In: Feagan BG, Kahrilas PJ, Jalan R, Mcdonald JWD, editors. Evidence-based Gastroenterology and Hepatology 4e. Chichester: John Wiley & Sons, Ltd; 2019. pp. 173-86. [DOI: 10.1002/9781119211419.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Simons FER. Anaphylaxis. Journal of Allergy and Clinical Immunology 2010;125:S161-81. [DOI: 10.1016/j.jaci.2009.12.981] [Cited by in Crossref: 263] [Cited by in F6Publishing: 186] [Article Influence: 21.9] [Reference Citation Analysis]
89 Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent: . Inflammatory Bowel Diseases 2011;17:99-104. [DOI: 10.1002/ibd.21370] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
90 Michielan A, Martinato M, Favarin A, Zanotto V, Caccaro R, Caruso A, Sturniolo GC, D’incà R. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease. Digestive and Liver Disease 2015;47:372-7. [DOI: 10.1016/j.dld.2015.01.152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
91 Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Review of Clinical Immunology 2014;8:43-54. [DOI: 10.1586/eci.11.75] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
92 Jönsson F, Mancardi DA, Albanesi M, Bruhns P. Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions. J Leukoc Biol 2013;94:643-56. [PMID: 23532517 DOI: 10.1189/jlb.1212623] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
93 Gallardo R, Fobelo MJ, Pastor C, Orta-Cuevas JC. [Protocol for inducing infliximab tolerance in a patient with psoriatic spondylarthritis]. Farm Hosp 2010;34:94-6. [PMID: 20304368 DOI: 10.1016/j.farma.2009.10.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Bao J, Yue T, Li T, He D, Bao Y. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist. Int J Rheum Dis 2016;19:370-6. [DOI: 10.1111/1756-185x.12387] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
95 Vultaggio A, Castells MC. Hypersensitivity Reactions to Biologic Agents. Immunology and Allergy Clinics of North America 2014;34:615-32. [DOI: 10.1016/j.iac.2014.04.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
96 Ancowitz B, Shah SA. Infusion services in the gastroenterology practice. Gastrointest Endosc Clin N Am 2006;16:727-42. [PMID: 17098619 DOI: 10.1016/j.giec.2006.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
97 O’neill I, Scully C. Biologics in oral medicine: principles of use and practical considerations: Biologics use and practical considerations. Oral Diseases 2012;18:525-36. [DOI: 10.1111/j.1601-0825.2012.01919.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
98 Hutsell SQ, Wu M, Park KT. Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications. J Pediatr Gastroenterol Nutr 2017;65:430-1. [PMID: 28937551 DOI: 10.1097/MPG.0000000000001535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 2.8] [Reference Citation Analysis]
99 Miyasaka N, Takeuchi T, Eguchi K. Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Modern Rheumatology 2014;15:4-8. [DOI: 10.3109/s10165-004-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
100 Khodoun MV, Kucuk ZY, Strait RT, Krishnamurthy D, Janek K, Clay CD, Morris SC, Finkelman FD. Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis. J Allergy Clin Immunol 2013;132:1375-87. [PMID: 24139828 DOI: 10.1016/j.jaci.2013.09.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
101 Kozma GT, Mészáros T, Vashegyi I, Fülöp T, Örfi E, Dézsi L, Rosivall L, Bavli Y, Urbanics R, Mollnes TE, Barenholz Y, Szebeni J. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions. ACS Nano 2019;13:9315-24. [PMID: 31348638 DOI: 10.1021/acsnano.9b03942] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
102 Diaz-Llopis M, García-Delpech S, Salom D, Udaondo P, Hernández-Garfella M, Bosch-Morell F, Quijada A, Romero FJ. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351-61. [PMID: 18476805 DOI: 10.1089/jop.2007.0104] [Cited by in Crossref: 84] [Cited by in F6Publishing: 68] [Article Influence: 6.0] [Reference Citation Analysis]
103 Pérez-Zafrilla B, Angel Descalzo M, Carmona L; y Grupo de Estudio BIOBADASER. [Adverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic Therapy]. Reumatol Clin 2008;4:90-5. [PMID: 21794507 DOI: 10.1016/S1699-258X(08)71810-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
104 Afzali A, Ogden K, Friedman ML, Chao J, Wang A. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting. Journal of Medical Economics 2017;20:409-22. [DOI: 10.1080/13696998.2017.1285779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
105 Mosli MH, Feagan BG. Combination therapy for the treatment of Crohn's disease. Expert Opin Biol Ther 2015;15:1429-42. [PMID: 26211474 DOI: 10.1517/14712598.2015.1065249] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
106 Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. [PMID: 17299059 DOI: 10.1136/gut.2006.106781] [Cited by in Crossref: 649] [Cited by in F6Publishing: 609] [Article Influence: 43.3] [Reference Citation Analysis]
107 Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
108 Su C, Lichtenstein GR. Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev. 2005;57:237-245. [PMID: 15555740 DOI: 10.1016/j.addr.2004.08.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
109 Bhat S, Sharma D, Doherty P, Tham TC, Caddy GR. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis. 2010;16:1922-1925. [PMID: 20848465 DOI: 10.1002/ibd.21279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
110 Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Advanced Drug Delivery Reviews 2020;154-155:163-75. [DOI: 10.1016/j.addr.2020.07.024] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 22.0] [Reference Citation Analysis]
111 Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007;6:75-92. [DOI: 10.1038/nrd2196] [Cited by in Crossref: 126] [Cited by in F6Publishing: 110] [Article Influence: 8.4] [Reference Citation Analysis]
112 Miheller P, Muzes G, Lakatos G, Mihály E, Tulassay Z. Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease. J Emerg Med 2007;32:209-10; author reply 210. [PMID: 17307639 DOI: 10.1016/j.jemermed.2006.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
113 Nelson AA, Pearce DJ, Fleischer Jr AB, Balkrishnan R, Feldman SR. Infliximab for inpatient psoriasis management – is there a role? Journal of Dermatological Treatment 2009;16:314-8. [DOI: 10.1080/09546630500335951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
114 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
115 Lie MR, Peppelenbosch MP, West RL, Zelinkova Z, van der Woude CJ. Adalimumab in Crohn’s disease patients: pharmacokinetics in the first 6 months of treatment. Aliment Pharmacol Ther. 2014;40:1202-1208. [PMID: 25263077 DOI: 10.1111/apt.12969] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
116 Feuerstein JD, Cullen G, Cheifetz AS. Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:1176-86. [DOI: 10.1097/mib.0000000000000279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
117 Cui D, Huang G, Yang D, Huang B, An B. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2013;37:507-13. [PMID: 23433962 DOI: 10.1016/j.clinre.2012.12.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
118 Savage WJ, Tobian AA, Savage JH, Wood RA, Schroeder JT, Ness PM. Scratching the surface of allergic transfusion reactions. Transfusion 2013;53:1361-71. [PMID: 22998777 DOI: 10.1111/j.1537-2995.2012.03892.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
119 Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC. Safety of Infliximab Treatment in Pediatric Patients with Inflammatory Bowel Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:265-9. [DOI: 10.1097/00005176-200409000-00008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
120 Wilson MW, Shergy WJ, Haik BG. Infliximab in the Treatment of Recalcitrant Idiopathic Orbital Inflammation. Ophthalmic Plastic & Reconstructive Surgery 2004;20:381-3. [DOI: 10.1097/01.iop.0000139521.38345.ba] [Cited by in Crossref: 30] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
121 Galvão VR, Castells MC. Hypersensitivity to Biological Agents—Updated Diagnosis, Management, and Treatment. The Journal of Allergy and Clinical Immunology: In Practice 2015;3:175-85. [DOI: 10.1016/j.jaip.2014.12.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
122 Joshi SR, Khan DA. Anaphylaxis Induced by Biologics. Curr Treat Options Allergy 2019;6:125-41. [DOI: 10.1007/s40521-019-00207-0] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006;24:851-8. [PMID: 16918890 DOI: 10.1111/j.1365-2036.2006.03026.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
124 Larsen L, Jess T, Drewes AM, Dige A, Fallingborg J, Jacobsen BA, Aagaard B, Agnholt J. Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. European Journal of Gastroenterology & Hepatology 2019;31:964-7. [DOI: 10.1097/meg.0000000000001440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Waldron JL, Schworer SA, Kwan M. Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. Clin Rev Allergy Immunol 2021. [PMID: 34319562 DOI: 10.1007/s12016-021-08879-w] [Reference Citation Analysis]
126 Khodoun MV, Strait R, Armstrong L, Yanase N, Finkelman FD. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A 2011;108:12413-8. [PMID: 21746933 DOI: 10.1073/pnas.1105695108] [Cited by in Crossref: 89] [Cited by in F6Publishing: 80] [Article Influence: 8.1] [Reference Citation Analysis]
127 Riddle C, Young M, Menter A. Practical considerations in future psoriasis therapies. Dermatologic Clinics 2004;22:487-92. [DOI: 10.1016/s0733-8635(03)00128-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
129 Hendler SA, Cohen BL, Colombel JF, Sands BE, Mayer L, Agarwal S. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. J Crohns Colitis. 2015;9:266-275. [PMID: 25540149 DOI: 10.1093/ecco-jcc/jju026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
130 Benucci M, Li Gobbi F, Meacci F, Manfredi M, Infantino M, Severino M, Testi S, Sarzi-Puttini P, Ricci C, Atzeni F. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics 2015;9:7-12. [PMID: 25733803 DOI: 10.2147/BTT.S69606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
131 Domènech E, Zabana Y, Mañosa M, Garcia-planella E, Cabré E, Gassull MÀ. Infliximab Reintroduction is Not Associated to a Higher Rate of Immune-related Adverse Effects in Patients With Inflammatory Bowel Disease Initially Treated With a Three-infusion Induction Regimen. Journal of Clinical Gastroenterology 2010;44:34-7. [DOI: 10.1097/mcg.0b013e3181962dfa] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
132 Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, Takeuchi T. Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:299-304. [PMID: 20980704 DOI: 10.1136/ard.2010.136283] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
133 Wee JS, Petrof G, Jackson K, Barker JN, Smith CH. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Br J Dermatol 2012;167:411-6. [PMID: 22404545 DOI: 10.1111/j.1365-2133.2012.10931.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
134 Vultaggio A, Nencini F, Pratesi S, Petroni G, Maggi E, Matucci A. Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. J Interferon Cytokine Res 2014;34:946-52. [PMID: 25493962 DOI: 10.1089/jir.2012.0139] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
135 Cáceres MC, Guerrero-Martín J, Pérez-Civantos D, Palomo-López P, Delgado-Mingorance JI, Durán-Gómez N. The importance of early identification of infusion-related reactions to monoclonal antibodies. Ther Clin Risk Manag 2019;15:965-77. [PMID: 31447561 DOI: 10.2147/TCRM.S204909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
136 Khan DA, Solensky R. Drug allergy. Journal of Allergy and Clinical Immunology 2010;125:S126-S137.e1. [DOI: 10.1016/j.jaci.2009.10.028] [Cited by in Crossref: 139] [Cited by in F6Publishing: 105] [Article Influence: 11.6] [Reference Citation Analysis]
137 Sutton BJ, Davies AM, Bax HJ, Karagiannis SN. IgE Antibodies: From Structure to Function and Clinical Translation. Antibodies (Basel) 2019;8:E19. [PMID: 31544825 DOI: 10.3390/antib8010019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
138 Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015;9:806-815. [PMID: 26092578 DOI: 10.1093/ecco-jcc/jjv096] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 13.9] [Reference Citation Analysis]
139 Urushima H, Nishimura J, Mizushima T, Hayashi N, Maeda K, Ito T. Perilla frutescens extract ameliorates DSS-induced colitis by suppressing proinflammatory cytokines and inducing anti-inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2015;308:G32-41. [PMID: 25359539 DOI: 10.1152/ajpgi.00294.2014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
140 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
141 Mcnamara D, Brophy S, Hyland J. Perianal Crohn's disease and infliximab therapy. The Surgeon 2004;2:258-63. [DOI: 10.1016/s1479-666x(04)80094-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
142 Filipe V, Hawe A, Schellekens H, Jiskoot W. Aggregation and Immunogenicity of Therapeutic Proteins. In: Wang W, Roberts CJ, editors. Aggregation of Therapeutic Proteins. Hoboken: John Wiley & Sons, Inc.; 2010. pp. 403-33. [DOI: 10.1002/9780470769829.ch10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
143 Gibbs BF, Streatfield C, Falcone FH. Basophils as critical orchestrators of Th2-type immune responses. Expert Review of Clinical Immunology 2014;5:725-34. [DOI: 10.1586/eci.09.47] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
144 Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. Journal of Dermatological Treatment 2009;15:280-94. [DOI: 10.1080/09546630410017275] [Cited by in Crossref: 217] [Cited by in F6Publishing: 186] [Article Influence: 16.7] [Reference Citation Analysis]
145 Desai D, Goldbach-Mansky R, Milner JD, Rabin RL, Hull K, Pucino F, Colburn N. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother 2009;43:967-72. [PMID: 19417117 DOI: 10.1345/aph.1L573] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
146 Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 2005;44:157-163. [PMID: 15637039 DOI: 10.1093/rheumatology/keh464] [Cited by in Crossref: 254] [Cited by in F6Publishing: 207] [Article Influence: 14.9] [Reference Citation Analysis]
147 Joseph M, Kochanski J, Goyal A. A Case of Epinephrin-associated Refractory Hypotension Secondary to Lactic Acidosis. Inflamm Bowel Dis 2021:izab268. [PMID: 34718560 DOI: 10.1093/ibd/izab268] [Reference Citation Analysis]
148 Hausmann OV, Seitz M, Villiger PM, Pichler WJ. The complex clinical picture of side effects to biologicals. Med Clin North Am 2010;94:791-804, xi-ii. [PMID: 20609863 DOI: 10.1016/j.mcna.2010.03.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
149 Khanna R, Feagan BG. Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. Curr Treat Options Gastro 2014;12:76-89. [DOI: 10.1007/s11938-013-0005-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
150 Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79-99. [PMID: 23569399 DOI: 10.2147/dhps.s28801] [Cited by in Crossref: 124] [Cited by in F6Publishing: 69] [Article Influence: 13.8] [Reference Citation Analysis]
151 Baker DL, Nakamura GR, Lowman HB, Fischer SK. Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis. AAPS J 2016;18:115-23. [PMID: 26340860 DOI: 10.1208/s12248-015-9821-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
152 Saeed SA, Crandall WV. Managing Crohn Disease in Children and Adolescents: Focus on Tumor Necrosis Factor Antagonists. Pediatric Drugs 2008;10:31-8. [DOI: 10.2165/00148581-200810010-00004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
153 Gupta A, Unglik G, Macrae FA. Bilateral parotidomegaly following anaphylaxis to infliximab: . Inflammatory Bowel Diseases 2009;15:1288-9. [DOI: 10.1002/ibd.20801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
154 Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, Caubet JC, Engler RJ, Gold MS, Ponvert C, Demoly P, Sanchez-Borges M, Muraro A, Li JT, Rottem M, Rosenwasser LJ. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J 2016;9:32. [PMID: 27679682 DOI: 10.1186/s40413-016-0120-5] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 11.0] [Reference Citation Analysis]
155 West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28:1122-1126. [PMID: 18691349 DOI: 10.1111/j.1365-2036.2008.03828.x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 146] [Article Influence: 10.9] [Reference Citation Analysis]
156 Baker MC, Weng Y, Fairchild R, Ahuja N, Rohatgi N. Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017. JAMA Netw Open 2021;4:e2110268. [PMID: 34081140 DOI: 10.1001/jamanetworkopen.2021.10268] [Reference Citation Analysis]
157 Taitt HA, Balakrishnan R. Spondyloarthritides. Emerg Med Clin North Am 2022;40:159-78. [PMID: 34782086 DOI: 10.1016/j.emc.2021.08.005] [Reference Citation Analysis]
158 Karasuyama H, Obata K, Wada T, Tsujimura Y, Mukai K. Newly appreciated roles for basophils in allergy and protective immunity: Newly recognized roles of basophils. Allergy 2011;66:1133-41. [DOI: 10.1111/j.1398-9995.2011.02613.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
159 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
160 Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005;41:357-9. [PMID: 16131995 DOI: 10.1097/01.mpg.0000169275.86308.b0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
161 Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769-779. [PMID: 23453887 DOI: 10.1016/j.crohns.2013.01.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
162 Kuhbacher T, Fölsch U. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007; 13(8): 1149-1155 [PMID: 17451192 DOI: 10.3748/wjg.v13.i8.1149] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
163 Reguia?? Z, Grange F. The Role of Anti-Tumor Necrosis Factor-?? Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease: . American Journal of Clinical Dermatology 2007;8:67-77. [DOI: 10.2165/00128071-200708020-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
164 Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007;120:506-15; quiz 516-7. [PMID: 17765751 DOI: 10.1016/j.jaci.2007.07.033] [Cited by in Crossref: 296] [Cited by in F6Publishing: 261] [Article Influence: 19.7] [Reference Citation Analysis]
165 Vultaggio A, Matucci A, Parronchi P, Rossi O, Palandri F, Romagnani S, Maggi E. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol 2008;21:367-74. [PMID: 18547481 DOI: 10.1177/039463200802100214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
166 Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol 2013;160:434-44. [PMID: 23215650 DOI: 10.1111/bjh.12150] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 8.3] [Reference Citation Analysis]
167 Abrantes FF, Moraes MPM, Albuquerque Filho JMV, Alencar JMD, Lopes AB, Pinto WBVR, Souza PVS, Oliveira EML, Oliveira ASB, Pedroso JL, Barsottini OGP. Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy. Arq Neuropsiquiatr 2021;79:1012-25. [PMID: 34816994 DOI: 10.1590/0004-282X-ANP-2020-0593] [Reference Citation Analysis]
168 Rozette NA, Hellauer CM, Mckee C, Vazifedan T, Gabriel CA, Dice JE, Yokois NU. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population. Inflammatory Bowel Diseases 2018;24:2007-14. [DOI: 10.1093/ibd/izy093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
169 Díaz-ley B, Guhl G, Fernández-herrera J. Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab. Actas Dermo-Sifiliográficas 2007;98:657-78. [DOI: 10.1016/s0001-7310(07)70159-x] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
170 Wang X, Cao J, Wang H, Ye C. Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study. Med Sci Monit 2019;25:2257-64. [PMID: 30917108 DOI: 10.12659/MSM.913152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
171 Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf 2021;:1-15. [PMID: 33910441 DOI: 10.1080/14740338.2021.1924147] [Reference Citation Analysis]
172 Finkelman FD. IgE-Dependent and Independent Effector Mechanisms in Human and Murine Anaphylaxis. In: Castells MC, editor. Anaphylaxis and Hypersensitivity Reactions. Totowa: Humana Press; 2011. pp. 127-44. [DOI: 10.1007/978-1-60327-951-2_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
173 Nucera E, Andriollo G, Buonomo A, Di Rienzo A, Scaldaferri F, Gasbarrini A, Aruanno A, Schiavino D. Interesting Case of Infliximab IV Type Hypersensitivity. Inflamm Bowel Dis 2019;25:e49-51. [PMID: 30265309 DOI: 10.1093/ibd/izy290] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Catt H, Bodger K, Kirkham JJ, Hughes DA. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease. PharmacoEconomics 2019;37:1509-23. [DOI: 10.1007/s40273-019-00826-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
175 Rojko JL, Evans MG, Price SA, Han B, Waine G, Dewitte M, Haynes J, Freimark B, Martin P, Raymond JT, Evering W, Rebelatto MC, Schenck E, Horvath C. Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes: Review and Case Studies. Toxicol Pathol 2014;42:725-64. [DOI: 10.1177/0192623314526475] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 11.0] [Reference Citation Analysis]
176 Picard M, Galvão VR. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. The Journal of Allergy and Clinical Immunology: In Practice 2017;5:600-9. [DOI: 10.1016/j.jaip.2016.12.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
177 Winterfield L, Menter A. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor α blockade. Dermatologic Clinics 2004;22:437-47. [DOI: 10.1016/j.det.2004.03.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
178 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
179 Escribese MM, Rosace D, Chivato T, Fernández TD, Corbí AL, Barber D. Alternative Anaphylactic Routes: The Potential Role of Macrophages. Front Immunol 2017;8:515. [PMID: 28533777 DOI: 10.3389/fimmu.2017.00515] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
180 Tran-Minh ML, Gornet JM, Maillet M, Houze P, Simon M, McLellan P, Hassid D, Vivier-Chicoteau J, Baudry C, Hammoudi N, Allez M. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study. J Crohns Colitis 2021;15:742-8. [PMID: 33205193 DOI: 10.1093/ecco-jcc/jjaa231] [Reference Citation Analysis]
181 Legnani P, Kornbluth A. Newer therapies for inflammatory bowel disease. Curr Treat Options Gastro 2004;7:161-7. [DOI: 10.1007/s11938-004-0037-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
182 Lindhaus C, Tittelbach J, Elsner P. Cutaneous side effects of TNF-alpha inhibitors. J Dtsch Dermatol Ges 2017;15:281-8. [PMID: 28252861 DOI: 10.1111/ddg.13200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
183 Winterfield LS, Menter A. Infliximab. Dermatol Ther 2004;17:409-26. [DOI: 10.1111/j.1396-0296.2004.04044.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
184 Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol 2016;51:1062-8. [PMID: 27002981 DOI: 10.3109/00365521.2016.1149883] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
185 Matucci A, Nencini F, Maggi E, Vultaggio A. Hypersensitivity reactions to biologics used in rheumatology. Expert Review of Clinical Immunology 2019;15:1263-71. [DOI: 10.1080/1744666x.2020.1684264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study: A 1-h infliximab infusion during maintenance therapy is safe. Alimentary Pharmacology & Therapeutics 2011;34:181-7. [DOI: 10.1111/j.1365-2036.2011.04699.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
187 Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety 2005;3:391-403. [DOI: 10.1517/14740338.3.5.391] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
188 Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
189 Baraliakos X, Braun J. Current concepts in the therapy of the spondyloarthritides. BioDrugs 2004;18:307-14. [PMID: 15377173 DOI: 10.2165/00063030-200418050-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
190 Gillis CM, Jönsson F, Mancardi DA, Tu N, Beutier H, Van Rooijen N, Macdonald LE, Murphy AJ, Bruhns P. Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice. J Allergy Clin Immunol 2017;139:1253-1265.e14. [PMID: 27568081 DOI: 10.1016/j.jaci.2016.06.058] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
191 Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors’ reply: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2011;34:404-5. [DOI: 10.1111/j.1365-2036.2011.04748.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
192 Mazzuoli S, Tricarico D, Demma F, Furneri G, Guglielmi FW. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients. PLoS One 2016;11:e0166443. [PMID: 27851772 DOI: 10.1371/journal.pone.0166443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
193 Duron C, Goutte M, Pereira B, Bommelaer G, Buisson A. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. European Journal of Gastroenterology & Hepatology 2015;27:705-11. [DOI: 10.1097/meg.0000000000000354] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
194 Bohra A, Rizvi QAA, Keung CYY, Vasudevan A, van Langenberg DR. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. World J Gastroenterol 2020; 26(36): 5437-5449 [PMID: 33024395 DOI: 10.3748/wjg.v26.i36.5437] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
195 Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486-504. [PMID: 19628303 DOI: 10.1016/j.jaad.2008.10.060] [Cited by in Crossref: 124] [Cited by in F6Publishing: 92] [Article Influence: 9.5] [Reference Citation Analysis]
196 Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol. 2009;23:101-112. [PMID: 19258190 DOI: 10.1016/j.bpg.2008.12.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
197 Singh M, Diwan MM, Patel KC. A rare case of supraventricular tachycardia induced by Infliximab: a case report. Cases J. 2009;2:147. [PMID: 19946518 DOI: 10.1186/1757-1626-2-147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
198 Gold SL, Cohen-mekelburg S, Schneider Y, Shen N, Faggen A, Rupert A, Scherl EJ, Bosworth B, Steinlauf A. Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study. Inflammatory Bowel Diseases 2017;23:1882-9. [DOI: 10.1097/mib.0000000000001189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
199 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
200 Wen S, Unuma K, Chinuki Y, Hikino H, Uemura K. Fatal anaphylaxis due to alpha-gal syndrome after initial cetuximab administration: The first forensic case report. Leg Med (Tokyo) 2021;51:101878. [PMID: 33892262 DOI: 10.1016/j.legalmed.2021.101878] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Li Y, Stocchi L, Rui Y, Remzi FH, Shen B. Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn’s disease following ileocolonic resection. Int J Colorectal Dis 2016;31:1751-8. [DOI: 10.1007/s00384-016-2632-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 . Management of Psoriatic Arthritis. Psoriatic and Reactive Arthritis. Elsevier; 2007. pp. 97-113. [DOI: 10.1016/b978-0-323-03622-1.50017-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
203 Yarur AJ, Abreu MT. Back to the beginning: restarting infliximab in inflammatory bowel disease patients with prior loss of response. Clin Gastroenterol Hepatol 2014;12:1482-4. [PMID: 24735794 DOI: 10.1016/j.cgh.2014.04.011] [Reference Citation Analysis]
204 Gisbert JP, Gomollón F. [Common errors in the management of the seriously ill patient with inflammatory bowel disease]. Gastroenterol Hepatol 2007;30:294-314. [PMID: 17493441 DOI: 10.1157/13101982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
205 Melichar B, Cerman J Jr, Malírová E. Successful management of infusion reaction accompanying the start of cetuximab therapy. Support Care Cancer 2007;15:445-9. [PMID: 17103198 DOI: 10.1007/s00520-006-0159-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
206 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
207 Faubion WA, Bousvaros A. Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 2006;4:1199-213. [DOI: 10.1016/j.cgh.2006.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
208 de Vries HS, van Oijen MG, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 2008;31:1135-44. [PMID: 19026030 DOI: 10.2165/0002018-200831120-00009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
209 Brandt J, Braun J. Anti-TNF-α agents in the treatment of psoriatic arthritis. Expert Opinion on Biological Therapy 2006;6:99-107. [DOI: 10.1517/14712598.6.2.99] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
210 Ebo DG, Clarke RC, Mertes P, Platt PR, Sabato V, Sadleir PH. Molecular mechanisms and pathophysiology of perioperative hypersensitivity and anaphylaxis: a narrative review. British Journal of Anaesthesia 2019;123:e38-49. [DOI: 10.1016/j.bja.2019.01.031] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
211 Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med 2019;8:E938. [PMID: 31261785 DOI: 10.3390/jcm8070938] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 16.0] [Reference Citation Analysis]
212 Yasui K, Matsuyama N, Takihara Y, Hirayama F. New insights into allergic transfusion reactions and their causal relationships, pathogenesis, and prevention. Transfusion 2020;60:1590-601. [DOI: 10.1111/trf.15845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
213 Nuñez F P, Quera R, Simian D, Flores L, Figueroa C, Ibañez P, Kronberg U, Lubascher J, Pizarro G. Infliximab in inflammatory bowel disease. Is premedication necessary? Gastroenterol Hepatol 2021;44:321-9. [PMID: 33386199 DOI: 10.1016/j.gastrohep.2020.07.018] [Reference Citation Analysis]
214 Baraliakos X, Braun J. Anti-TNF-α therapy with infliximab in spondyloarthritides. Expert Review of Clinical Immunology 2014;6:9-19. [DOI: 10.1586/eci.09.61] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
215 Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009;54:269-278. [PMID: 19934608 DOI: 10.4166/kjg.2009.54.2.108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
216 Khan BQ, Kemp SF. Pathophysiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2011;11:319-25. [PMID: 21659865 DOI: 10.1097/ACI.0b013e3283481ab6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
217 Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2019;15:527-39. [PMID: 31177858 DOI: 10.1080/17425255.2019.1630378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
218 Picoraro J, Winberry G, Siegel CA, El-Matary W, Moses J, Grossman A, Park KT. Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. Inflamm Bowel Dis 2017;23:174-80. [PMID: 28002131 DOI: 10.1097/MIB.0000000000001002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
219 Szymanska E, Dadalski M, Sieczkowska-Golub J, Jarzebicka D, Meglicka M, Osiecki M, Wiernicka A, Lebensztejn DM, Korczowski B, Kierkus J. Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease-A Single Center Case-Control Study. J Clin Med 2021;10:3177. [PMID: 34300342 DOI: 10.3390/jcm10143177] [Reference Citation Analysis]
220 Eto A, Nakahara T, Furue M. Repeated infliximab injection may shift delayed infusion reactions to acute infusion reactions in patients with psoriasis. J Dermatol 2021;48:e41-2. [PMID: 33073412 DOI: 10.1111/1346-8138.15652] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
221 Jacobstein DA, Markowitz JE, Kirschner BS, Ferry G, Cohen SA, Gold BD, Winter HS, Heyman MB, Baldassano RN. Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium: . Inflammatory Bowel Diseases 2005;11:442-6. [DOI: 10.1097/01.mib.0000158166.88238.ea] [Cited by in Crossref: 65] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
222 Saxena P, Chen G, Jideh B, Collins G, Leong RW. Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases. Expert Opinion on Biological Therapy 2013;14:277-82. [DOI: 10.1517/14712598.2014.866649] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
223 Lebas D, Staumont-sallé D, Solau-gervais E, Flipo R, Delaporte E. Manifestations cutanées observées au cours d’un traitement par anti-TNF alpha : 11 observations. Annales de Dermatologie et de Vénéréologie 2007;134:337-42. [DOI: 10.1016/s0151-9638(07)89187-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
224 Subedi S, Gong Y, Chen Y, Shi Y. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019;13:2491-2502. [PMID: 31413544 DOI: 10.2147/dddt.s200147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
225 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD005112. [PMID: 16856078 DOI: 10.1002/14651858.cd005112.pub2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
226 Fumery M, Tilmant M, Yzet C, Brazier F, Loreau J, Turpin J, Le Mouel JP, Goeb V, Nguyen-khac E, Singh S, Dupas J, Diouf M. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. Digestive and Liver Disease 2019;51:484-8. [DOI: 10.1016/j.dld.2018.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
227 Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas A. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre: Clinic’s experience with infliximab. British Journal of Dermatology 2010;162:1117-23. [DOI: 10.1111/j.1365-2133.2009.09578.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
228 Barfield E, Sockolow R, Hoffenberg E, Saeed S, Kim S, Siebold L, Picoraro J, Moses J, Dykes D, Grossman A, Wahbeh G, Park KT. Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:680-6. [PMID: 29324477 DOI: 10.1097/MPG.0000000000001890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
229 Mease P. Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag 2006;2:389-400. [PMID: 18360651 DOI: 10.2147/tcrm.2006.2.4.389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
230 van Schie KA, Ooijevaar-De Heer P, Kruithof S, Plasencia C, Jurado T, Pascual Salcedo D, Brandse JF, d'Haens GR, Wolbink GJ, Rispens T. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. Ann Rheum Dis 2017;76:1285-8. [PMID: 28455438 DOI: 10.1136/annrheumdis-2016-211035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
231 Bavbek S, Kendirlinan R, Çerçi P, Altıner S, Soyyiğit Ş, Çelebi Sözener Z, Aydın Ö, Gümüşburun R. Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics. Int Arch Allergy Immunol 2017;171:227-33. [DOI: 10.1159/000454808] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
232 Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin Pharmacother 2006;7:1907-18. [PMID: 17020417 DOI: 10.1517/14656566.7.14.1907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
233 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 516] [Article Influence: 46.6] [Reference Citation Analysis]
234 Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798-805. [PMID: 17417731 DOI: 10.1007/s10620-006-9269-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
235 Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 2005;34:178-90. [PMID: 16134723 DOI: 10.1080/03009740510026599] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
236 Szymanska E, Dadalski M, Oracz G, Kierkus J. Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease. Prz Gastroenterol 2015;10:164-8. [PMID: 26516383 DOI: 10.5114/pg.2015.52298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
237 Feuerstein JD, Cheifetz AS. Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy). Gastroenterology Clinics of North America 2014;43:543-63. [DOI: 10.1016/j.gtc.2014.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
238 Hirten R, Sultan K, Thomas A, Bernstein DE. Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol 2015; 7(27): 2716-2728 [PMID: 26644815 DOI: 10.4254/wjh.v7.i27.2716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
239 Sattler L, Hanauer SB, Malter L. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep 2021;23:30. [PMID: 34913108 DOI: 10.1007/s11894-021-00829-y] [Reference Citation Analysis]
240 Scavone C, Sportiello L, Sullo MG, Ferrajolo C, Ruggiero R, Sessa M, Berrino PM, di Mauro G, Berrino L, Rossi F, Rafaniello C, Capuano A; BIO-Cam Group. Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. Front Pharmacol 2017;8:607. [PMID: 28932193 DOI: 10.3389/fphar.2017.00607] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
241 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
242 Benucci M, Saviola G, Meacci F, Manfredi M, Infantino M, Campi P, Severino M, Iorno M, Sarzi-Puttini P, Atzeni F. No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis. Open Rheumatol J 2013;7:75-80. [PMID: 24115967 DOI: 10.2174/1874312901307010075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
243 Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hébuterne X, Treton X, Kohn A. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92-101. [PMID: 19709098 DOI: 10.1111/j.1365-2036.2009.04130.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
244 Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55-63. [PMID: 21162650 DOI: 10.1586/eci.10.90] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
245 Ducharme J, Pelletier C, Zacharias R. Premedications for infliximab infusions do not impact the risk of acute adverse drug reactions. Frontline Gastroenterol 2011;2:249-54. [PMID: 28839619 DOI: 10.1136/flgastro-2011-100030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
246 Mössner R, Schön MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clinics in Dermatology 2008;26:486-502. [DOI: 10.1016/j.clindermatol.2007.10.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
247 Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2011;5:679-84. [PMID: 22017695 DOI: 10.1586/egh.11.81] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
248 Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammüller M. The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. Front Immunol 2020;11:472. [PMID: 32296421 DOI: 10.3389/fimmu.2020.00472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
249 Lambert JLW, De Schepper S, Speeckaert R. Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review. J Clin Med 2021;10:1040. [PMID: 33802483 DOI: 10.3390/jcm10051040] [Reference Citation Analysis]
250 Vilar P, de Carpi JM, Acuña CE, Masiques ML. Infliximab in paediatric inflammatory bowel disease. Journal of Crohn's and Colitis 2007;1:2-9. [DOI: 10.1016/j.crohns.2007.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
251 Behera SK, Selvarajan S, Mathews J, Shajil C, Das S, Munisamy M, Xavier AS. A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis. Curr Drug Saf 2019;14:158-62. [PMID: 30659548 DOI: 10.2174/1574886314666190119115632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
252 Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:51-58. [PMID: 21535447 DOI: 10.1111/j.1365-2036.2011.04682.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 9.9] [Reference Citation Analysis]
253 Simons FE. Anaphylaxis: Recent advances in assessment and treatment. J Allergy Clin Immunol 2009;124:625-36; quiz 637-8. [PMID: 19815109 DOI: 10.1016/j.jaci.2009.08.025] [Cited by in Crossref: 156] [Cited by in F6Publishing: 104] [Article Influence: 12.0] [Reference Citation Analysis]
254 Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109-1117. [PMID: 18337601 DOI: 10.1056/nejmoa074943] [Cited by in Crossref: 973] [Cited by in F6Publishing: 333] [Article Influence: 69.5] [Reference Citation Analysis]
255 Hubbard V, Friedmann A, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005;152:1059-61. [DOI: 10.1111/j.1365-2133.2005.06467.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
256 Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7:289-300. [PMID: 28839870 DOI: 10.1136/flgastro-2016-100685] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
257 Bultman E, de Haar C, van Liere-Baron A, Verhoog H, West RL, Kuipers EJ, Zelinkova Z, van der Woude CJ. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. Aliment Pharmacol Ther. 2012;35:335-341. [PMID: 22191671 DOI: 10.1111/j.1365-2036.2011.04946.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
258 Lahdenne P, Wikström AM, Aalto K, Kolho KL. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res (Hoboken) 2010;62:785-90. [PMID: 20535789 DOI: 10.1002/acr.20246] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
259 Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008;28:221-7. [PMID: 18485127 DOI: 10.1111/j.1365-2036.2008.03734.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
260 Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008;159:527-36. [PMID: 18627374 DOI: 10.1111/j.1365-2133.2008.08728.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
261 Pritchard CW, Hawthorne AB. Managing immunosuppression in medical patients. Br J Hosp Med (Lond) 2009;70:394-8. [PMID: 19584781 DOI: 10.12968/hmed.2009.70.7.43122] [Reference Citation Analysis]
262 Hashimoto N, Mitani S, Taniguchi H, Narita Y, Kato K, Masuishi T, Kadowaki S, Onishi S, Tajika M, Takahashi S, Shimomura K, Takahata C, Hotta E, Kobara M, Muro K. A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer. Oncologist 2019;24:159-e66. [PMID: 30305415 DOI: 10.1634/theoncologist.2018-0580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
263 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
264 Kemp SF, Lockey RF. Pathophysiology and Organ Damage in Anaphylaxis. In: Castells MC, editor. Anaphylaxis and Hypersensitivity Reactions. Totowa: Humana Press; 2011. pp. 33-46. [DOI: 10.1007/978-1-60327-951-2_3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
265 Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228-1239. [PMID: 20955442 DOI: 10.1111/j.1365-2036.2010.04466.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 85] [Article Influence: 8.2] [Reference Citation Analysis]
266 Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol 2021;147:1123-31. [PMID: 33832694 DOI: 10.1016/j.jaci.2021.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
267 Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005;64 Suppl 2:ii78-82. [PMID: 15708944 DOI: 10.1136/ard.2004.034157] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
268 Bartoli F, Bruni C, Cometi L, Blagojevic J, Fiori G, Tofani L, Galluccio F, Furst DE, Matucci Cerinic M. Premedication prevents infusion reactions and improves retention rate during infliximab treatment. Clin Rheumatol 2016;35:2841-5. [DOI: 10.1007/s10067-016-3351-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
269 Ariza A, Torres MJ, Moreno-aguilar C, Fernández-santamaría R, Fernández TD. Early Biomarkers for Severe Drug Hypersensitivity Reactions. CPD 2019;25:3829-39. [DOI: 10.2174/1381612825666191107105440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
270 Checkley LA, Kristofek L, Kile S, Bolgar W. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting. Dig Dis Sci 2019;64:855-62. [PMID: 30311152 DOI: 10.1007/s10620-018-5319-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
271 Daugherty AL, Mrsny RJ. Formulation and Delivery Issues for Monoclonal Antibody Therapeutics. In: Shire SJ, Gombotz W, Bechtold-peters K, Andya J, editors. Current Trends in Monoclonal Antibody Development and Manufacturing. New York: Springer; 2010. pp. 103-29. [DOI: 10.1007/978-0-387-76643-0_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
272 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
273 Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011; 17(27): 3204-3212 [PMID: 21912469 DOI: 10.3748/wjg.v17.i27.3204] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
274 Chang JT, Lichtenstein GR. Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2006;3:220-8. [DOI: 10.1038/ncpgasthep0447] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
275 Devlin SM, Panaccione R. Adalimumab for the treatment of Crohn's disease. Expert Opin Biol Ther 2008;8:1011-9. [PMID: 18549330 DOI: 10.1517/14712598.8.7.1011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
276 Behm BW, Bickston SJ. Medical management of Crohn's disease: current therapy and recent advances. Expert Review of Clinical Immunology 2014;2:109-20. [DOI: 10.1586/1744666x.2.1.109] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
277 Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:501-5. [DOI: 10.1007/s11894-003-0040-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
278 Vaughn BP. A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease. J Clin Med 2021;10:4990. [PMID: 34768509 DOI: 10.3390/jcm10214990] [Reference Citation Analysis]
279 Duarte AA, Chehin FB. Psoríase moderada a grave tratada com infliximabe em 53 pacientes: perfil dos pacientes, eficácia e efeitos adversos. An Bras Dermatol 2011;86:257-63. [DOI: 10.1590/s0365-05962011000200008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
280 Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol 2016;137:1674-80. [PMID: 27130857 DOI: 10.1016/j.jaci.2016.02.015] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 20.7] [Reference Citation Analysis]
281 Saraceno R, Saggini A, Pietroleonardo L, Chimenti S. Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol 2009;2:27-37. [PMID: 21436966 DOI: 10.2147/ccid.s3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
282 Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. World J Gastrointest Pharmacol Ther 2017; 8(2): 131-136 [PMID: 28533923 DOI: 10.4292/wjgpt.v8.i2.131] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
283 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
284 Marzano AV, Borghi A, Meroni PL, Crosti C, Cugno M. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity 2014;47:146-53. [PMID: 24437626 DOI: 10.3109/08916934.2013.873414] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
285 Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-33; quiz 591. [PMID: 16472588 DOI: 10.1053/j.gastro.2005.11.030] [Cited by in Crossref: 1055] [Cited by in F6Publishing: 961] [Article Influence: 65.9] [Reference Citation Analysis]
286 Descotes J. Immunotoxicology: role in the safety assessment of drugs. Drug Saf 2005;28:127-36. [PMID: 15691223 DOI: 10.2165/00002018-200528020-00004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
287 O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1-6. [PMID: 24280879 DOI: 10.1097/01.mib.0000436951.80898.6d] [Cited by in Crossref: 98] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
288 Mansi L, Thiery-vuillemin A, Nguyen T, Bazan F, Calcagno F, Rocquain J, Demarchi M, Villanueva C, Maurina T, Pivot X. Safety profile of new anticancer drugs. Expert Opinion on Drug Safety 2009;9:301-17. [DOI: 10.1517/14740330903530663] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
289 Li Q, Ding X, Liu Y, Marcella C, Dai M, Zhang T, Bai J, Xiang L, Wen Q, Cui B, Zhang F. Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn's Disease. Front Pharmacol 2021;12:658087. [PMID: 34079458 DOI: 10.3389/fphar.2021.658087] [Reference Citation Analysis]
290 Reber LL, Sibilano R, Mukai K, Galli SJ. Potential effector and immunoregulatory functions of mast cells in mucosal immunity. Mucosal Immunol 2015;8:444-63. [PMID: 25669149 DOI: 10.1038/mi.2014.131] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 10.6] [Reference Citation Analysis]
291 Sala-cunill A, Guilarte M, Cardona V. Phenotypes, endotypes and biomarkers in anaphylaxis: current insights. Current Opinion in Allergy & Clinical Immunology 2018;18:370-6. [DOI: 10.1097/aci.0000000000000472] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
292 Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol 2017;140:335-48. [PMID: 28780941 DOI: 10.1016/j.jaci.2017.06.003] [Cited by in Crossref: 144] [Cited by in F6Publishing: 120] [Article Influence: 28.8] [Reference Citation Analysis]
293 Connell W, Andrews JM, Brown S, Sparrow M. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia: Safety of anti TNF treatment in IBD. Internal Medicine Journal 2010;40:139-49. [DOI: 10.1111/j.1445-5994.2009.02122.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
294 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 68.8] [Reference Citation Analysis]
295 Xue Y, Cohen JM, Wright NA, Merola JF. Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects. Am J Clin Dermatol 2016;17:147-62. [PMID: 26649439 DOI: 10.1007/s40257-015-0167-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
296 Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1-31.15. [PMID: 17097378 DOI: 10.1016/j.jaad.2006.07.017] [Cited by in Crossref: 332] [Cited by in F6Publishing: 301] [Article Influence: 20.8] [Reference Citation Analysis]
297 Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041] [Cited by in Crossref: 1456] [Cited by in F6Publishing: 1258] [Article Influence: 91.0] [Reference Citation Analysis]
298 Jönsson F, de Chaisemartin L, Granger V, Gouel-chéron A, Gillis CM, Zhu Q, Dib F, Nicaise-roland P, Ganneau C, Hurtado-nedelec M, Paugam-burtz C, Necib S, Keita-meyer H, Le Dorze M, Cholley B, Langeron O, Jacob L, Plaud B, Fischler M, Sauvan C, Guinnepain M, Montravers P, Aubier M, Bay S, Neukirch C, Tubach F, Longrois D, Chollet-martin S, Bruhns P. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci Transl Med 2019;11:eaat1479. [DOI: 10.1126/scitranslmed.aat1479] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
299 Ally MR, Betteridge JD, Veerappan GR. Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose. Inflamm Bowel Dis 2012;18:E1592-3. [PMID: 22231796 DOI: 10.1002/ibd.21909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
300 Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV; American Academy of Allergy, Asthma & Immunology., American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373-7. [PMID: 17996286 DOI: 10.1016/j.jaci.2007.09.032] [Cited by in Crossref: 179] [Cited by in F6Publishing: 150] [Article Influence: 11.9] [Reference Citation Analysis]
301 Babouri A, Buisson A, Bigard M, Peyrin-biroulet L. Tolerability of one hour 10mg/kg infliximab infusions in patients with inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:129-33. [DOI: 10.1016/j.crohns.2012.03.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
302 Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:71-75. [PMID: 19060632 DOI: 10.1097/meg.0b013e3283081afe] [Cited by in Crossref: 29] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
303 Chamberlain P. Presenting an Immunogenicity Risk Assessment to Regulatory Agencies. In: Weert MVD, Møller EH, editors. Immunogenicity of Biopharmaceuticals. New York: Springer; 2008. pp. 239-58. [DOI: 10.1007/978-0-387-75841-1_13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
304 Qazi T, Shah B, El-Dib M, Farraye FA. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2016;61:589-96. [PMID: 26441281 DOI: 10.1007/s10620-015-3893-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
305 Eichele DD, Young R. Medical Management of Inflammatory Bowel Disease. Surg Clin North Am 2019;99:1223-35. [PMID: 31676060 DOI: 10.1016/j.suc.2019.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
306 Uthman I, Touma Z, El-sayyad J, Zaitoun F. Successful retreatment with infliximab in patients with prior severe infusion reactions. Clin Rheumatol 2006;25:540-1. [DOI: 10.1007/s10067-005-0029-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
307 Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA. To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev 2021;180:114079. [PMID: 34902516 DOI: 10.1016/j.addr.2021.114079] [Reference Citation Analysis]
308 Weiner JJ, Eudy AM, Criscione-schreiber LG. How Well Do Rheumatology Fellows Manage Acute Infusion Reactions? A Pilot Curricular Intervention. Arthritis Care Res 2018;70:931-7. [DOI: 10.1002/acr.23417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
309 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
310 Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F. Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry. J Rheumatol 2015;42:1105-11. [DOI: 10.3899/jrheum.140538] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]